Investment Rating - The report maintains a Neutral rating for Futu Holdings since July 14, 2021 [10]. Core Insights - Futu reported a positive net profit growth in 1Q25, primarily due to better-than-expected cost savings and a reduction in client acquisition costs (CAC) [1]. - The management's guidance for 2025 indicates that CAC will remain high due to market volatility, despite the positive performance in 1Q25 [1][2]. - The guidance for paying user growth in 2025 is set at 800,000, reflecting a cautious outlook given the anticipated slowdown in new user growth starting from 2Q25 [2]. - A lower HIBOR rate is expected to negatively impact interest income growth, with management indicating that a 25 basis points rate cut could lead to a pre-tax profit decrease of HK$ 8-10 million per month [3]. - The report highlights the potential positive impact of stablecoin adoption, AI integration, and market expansion into regions like Japan and New Zealand on Futu's competitive edge [16]. Financial Estimates - The revenue estimates for 2025 have been slightly adjusted downwards by 1%, while net profit estimates have been revised upwards by 4% [17]. - The new target price for Futu is set at US$ 111.11, reflecting a 3% decrease from the previous target [17]. - The report projects total revenue for 2025 at HK$ 17,039.5 million, with net income expected to reach HK$ 6,600.1 million, indicating a growth rate of 21.5% [5][13]. Key Data - Futu's market capitalization is reported at US$ 15.0 billion [5]. - The company is positioned within the China Brokers & Asset Management sector, with a notable M&A rank of 3 [5]. - The report outlines a projected EPS of HK$ 47.74 for 2025, with a P/E ratio of 17.7 [10][5].

Investment Rating - The report assigns a "Buy" rating for CSPC Pharma with a 12-month price target of HK$8.74, indicating an upside potential of 14.7% from the current price of HK$7.62 [13][14]. Core Insights - The report highlights that CSPC Pharma experienced a revenue decline of 22% in Q1, primarily due to a high base in Q1 2024, ongoing pressure from volume-based procurement (VBP), and a 12.5% price cut for NBP injection [1]. - Despite the revenue miss, earnings showed resilience, supported by out-licensing income and significant expense cuts, particularly in selling expenses [1]. - Management has revised its guidance for 2025, focusing on sequential improvement rather than positive sales growth, and plans to pursue three more business development (BD) deals with a potential total deal size exceeding US$5 billion [2][8]. Summary by Sections Revenue and Earnings Performance - CSPC Pharma's sales in Q1 declined by 22% year-on-year, with finished drug sales down 27% year-on-year [1]. - Earnings for Q1 were reported at Rmb1.5 billion, an 8% decrease year-on-year, but were bolstered by Rmb718 million from out-licensing [1]. - Core earnings, excluding BD income, are estimated to have declined by approximately 45% year-on-year [1]. Business Development and Licensing - The company is actively negotiating three potential BD deals, with one expected to close in June, focusing on SYS6010 (EGFR ADC) and other technology collaborations [2]. - In Q1, CSPC Pharma booked US$40 million from the AZ deal and US$60 million from the BeOne deal, with expectations of over Rmb1 billion in additional income from new deals throughout the year [2]. Clinical Development and Pipeline - SYS6010 is prioritized for clinical development, with ongoing phase 3 studies for NSCLC and plans for further trials in various solid tumors [3][7]. - The company is preparing for pivotal studies outside China and aims to apply for breakthrough designation for certain assets [7]. Shareholder Returns and Incentives - CSPC Pharma plans to utilize operational cash flow for R&D and higher dividends, with a share buyback target of up to HK$5 billion over the next 24 months [8]. - A share-based incentive program is set to cover 200-300 key staff, with additional coverage planned for the second half of 2025 [8]. Financial Projections - Earnings estimates have been revised down by 7.7% for 2025 due to lower-than-expected finished drug sales, but the price target has increased from HK$7.84 to HK$8.74 [9]. - Revenue projections for 2025 are set at Rmb30.1 billion, with expectations of gradual recovery in subsequent years [14].

Investment Rating - The report provides a "Buy" rating for AstraZeneca, indicating strong confidence in its growth potential, particularly with the SERD class breast cancer therapy [2]. Core Insights - The utility sector is entering a new era characterized by localized and defensive growth, with electricity demand and revenues on the rise after a 15-year decline. The modernization of the power grid is essential to enhance energy security and meet the demands of renewable energy and data centers [1]. - AstraZeneca's SERD therapy is expected to become a key focus in the upcoming ASCO meeting, with a potential market value exceeding $15 billion by 2035, driven by a patient population of over 5 million globally [2]. - The report highlights SSE and National Grid as top picks in the UK utility sector due to their significant domestic market exposure and positive revenue trajectories [1]. Summary by Sections Utility Sector - The report discusses the necessity for Europe to invest approximately €2 trillion to modernize its electricity systems after years of underinvestment [1]. - Key topics include the recent power outage in Spain and its implications for the utility sector [1]. Pharmaceutical Sector - AstraZeneca's camizestrant is viewed as a critical growth driver, particularly for patients who have undergone endocrine therapy, positioning the company favorably against Roche [2]. - The report anticipates that the complete data presentation for camizestrant could serve as a market catalyst, reflecting its unique positioning and value [2]. Retail and Consumer Goods - The UK clothing market saw a year-on-year growth of 1.4% in the 12 weeks ending April 27, with Zara and M&S leading in sales growth [3]. - In the US, beauty product sales slowed in May, while Beiersdorf outperformed other brands in the skincare segment [3]. Beverage Sector - US beer sales declined by 3.7% over a 12-week period, while the spirits market saw a 3.8% drop, with ABI and STZ receiving a buy rating for gaining market share [4][5].

28日5月2025年 | 上午6:39香港时间 +852-2978-1681 | verena.jeng@ gs.com 高盛集团（亚洲）有限责任 公司Ting Song +852-2978-6466 | ting.song@g s.com 高盛公司（亚洲）有限责任 公司 GC Telecom：5G BTS月环比下降；4月电信服务收入同 比增长2%。 ：2025年4月，5G基站部署疲软，达44千个，同比减少，截至2025年4月累计基站 部署达440万个；基站产量同比2025年4月增长26%，出口 1) 中国电信服务业收入同比增长2%。 一个强劲的表现： 1) 4月份达到1516亿元人民币，较2025年3月的同比增长0.3%（根据工信部数据） ；2) 2025年4月5G新基站部署增速放缓，新增44万个单位，而2024年4月新增101万 个单位，2025年3月新增70万个单位；3) 5G用户增长增速放缓，2025年4月新增130 0万用户，而2024年4月新增1500万用户。光纤光缆、BTS和PCB出口的海外市场价 值同比增长，而CCL出口价值在2025年4月下降。 艾伦·张 +852-2978-2930 | a ...

Investment Rating - The report assigns a neutral rating to Hilton Hotels and a bearish rating to Amorepacific and LG Household & Health Care [2]. Core Insights - The Korean cosmetics industry is experiencing a decline in duty-free sales (DFS), with April 2025 showing a 10% year-over-year decrease, an improvement from a 16% decline in March 2025 [4][6]. - In the U.S. market, Korean cosmetics exports continued to grow, with a 21% year-over-year increase in April 2025, although some brands like COSRX are struggling with inventory issues [11][21]. - The Chinese market is showing a decline in online sales, with major platforms experiencing a 31% to 42% year-over-year drop [2]. Summary by Sections Duty-Free Sales Performance - April 2025 DFS revenue reached $822 million, down 10% year-over-year, primarily due to declines in local and foreign sales [4][6]. - The total DFS revenue for April 2025 is 47% of the level seen in April 2019, compared to 39% in March 2025 [7]. U.S. Market Insights - Korean cosmetics exports to the U.S. in April 2025 increased by 13%, contributing to a total export growth of 21% [11][16]. - COSRX's sales on Amazon in the U.S. fell by 38% year-over-year, while Laneige saw a 73% increase in the same period [21][24]. Chinese Market Dynamics - The report highlights a significant decline in online sales across major platforms in China, with declines ranging from 31% to 42% year-over-year [2]. - Local brands are gaining market share, with multinational companies experiencing varying degrees of growth and decline [52].

2025年5月27日 | 晚上7:58 EDT Shoals Technologies .SHLS 虚拟投资者会议的要点；买入 | | | 我们举办了一场与SHLS首席执行官Brandon Moss及财务与投资 者关系副总裁Matt Tractenberg的虚拟投资者会议，以讨论关键 竞争动态、近期关税和政策变化的影响、近期及长期需求趋势等 议题。我们此次通话的关键要点已在文中进行了更详细的总结。 Implications Following NXT's recent acquisition of 竞争动态。 eBOS公司Bentek，人们曾担忧SHLS的竞争定位可能存在风险。然 而在我们的电话会议中，SHLS管理层讨论了Bentek历来更多地涉 及组合箱和其他电气外壳，同时还提供一种绝缘刺穿连接器（IPC ）干线总线系统，该系统很少直接与SHLS竞争。重要的是，管理 层指出Bentek的IPC产品与SHLS的BLA产品有几个关键差异，因为 后者是在现场安装而非预组装，并且不具备可持续25-30年的同等 产品质量。因此，这些产品可能更专注于小型站点或对成本更敏感 的客户，而非在速度和质量至关重要的大型项目中。 ...

Investment Rating - The report maintains a "Buy" rating for Mitsubishi Electric (Melco) [1][5][22]. Core Insights - Mitsubishi Electric is undergoing a significant transformation, shifting from a product sales-based business model to one that leverages data extracted from components, focusing on miniaturization and discontinuing non-strategic businesses [2][5]. - The company plans to invest in data center optical devices instead of power components due to a slowdown in xEV applications, and aims to localize its FA operations [2]. - Melco is targeting a shareholder return rate of 50% or higher and aims to maintain a debt-to-equity ratio of 0.3x [4][10]. Summary by Relevant Sections Business Strategy - Melco expects sales to grow from ¥2.1 trillion and an operating profit margin of 6.6% in FY3/22 to ¥2.5 trillion and 9.3% in FY3/26, despite lower-than-expected trends in fixed asset control systems [8]. - The company plans to terminate businesses generating ¥0.5 trillion in sales as part of its portfolio review [8]. Cost Reduction - The company is focused on rapid cost reductions, particularly in China, to address challenges faced by its operations [3]. Capital Allocation - Melco is considering mergers and acquisitions (M&A) in growth sectors such as industrial, HVAC, and AI/digital technologies, with a new M&A budget set at ¥1 trillion through FY3/28 [4][10]. - The company aims to enhance profitability by improving operational efficiency and reallocating resources [10]. Financial Performance - Melco forecasts sales of approximately ¥680 billion for FY3/26, with a target of achieving at least 10% growth in operating profit margin [11][9]. - The company plans to increase production capacity in response to strong orders in its defense business and aims to restore operating profit margins to over 10% through restructuring and cost reductions [5][12]. Semiconductor and Device Business - Melco intends to limit investments in power devices while shifting focus to high-performing optical devices, with plans to accelerate the expansion of its HVDC power module business [20][21]. - The company aims to increase its optical device sales by over 20% annually [21].

28 May 2025 | 7:02PM AEST Fisher & Paykel Healthcare Corp. (FPH.AX): FY25 Result: Multi-year growth opportunity. Retain Buy FPH delivered a strong FY25 result with total revenue and NPAT broadly in line with our estimates and ahead of Visible Alpha Consensus Data by ~1% and ~4%. Looking ahead - the momentum of FPH's Hospital business (~60% FY25 group revenue) remains solid (Gse: +14% FY26) with key new products including Optiflow Switch and Airvo 3 NIV in the US market not materially contributing to FY26 gu ...

Investment Ratings - Petrobras: Buy with a 12-month price target of BRL 38.80 [18] - Brava Energia: Sell with a 12-month price target of BRL 15.80 [19] - PetroReconcavo: Neutral with a 12-month price target of BRL 16.50 [20] - Ultrapar: Buy with a 12-month price target of BRL 22.40 [21] - Cosan: Neutral with a 12-month price target of BRL 9.10 [22] - Vibra Energia: Neutral with a 12-month price target of BRL 20.30 [23] Core Insights - The report highlights a cautious outlook for oil prices, with expectations of average Brent oil prices at USD 56/bbl in 2026, influenced by solid supply growth outside the US shale [14] - Companies in the oil and gas sector are adjusting their capital expenditure (CAPEX) plans in response to lower oil prices, with Brava already reducing its investment plan for 2025 [2][12] - The fuel distribution segment is facing challenges from inventory losses due to recent price reductions by Petrobras, which may lead to lower margins in the short term [3][8] Summary by Company Petrobras - CAPEX remains resilient with 98% of upstream investments breakeven at or below USD 45/bbl, indicating no major adjustments in the short term [7] - The company is cautious about shareholder remuneration, recognizing potential increases in indebtedness due to lower oil prices [7] - Petrobras aims to avoid passing global market volatility to domestic fuel prices while aligning with international trends [7] Brava Energia - The company plans to deploy USD 450 million in CAPEX for 2025, a reduction from previous plans, primarily affecting onshore investments [12] - Brava expects stable production in the upcoming years, with potential growth in offshore output by 2026 [12] - The decision to cancel the divestment of onshore assets reflects a strategy to maintain a diversified portfolio [12] Vibra Energia - EBITDA in 2Q will be impacted by inventory losses, with a focus on reducing indebtedness through a 40% dividend payout policy [8] - Recent market share data indicates a slight increase in diesel market share, attributed to sales to TRR and unbranded gas stations [8] - The company does not foresee significant impacts from sanctions on Russian diesel imports [8] Ultrapar - The fuel distribution business is experiencing an oversupply effect, but demand is expected to improve in the second half of the year [9] - Ultrapar is positioning Ultragaz for potential investments in renewables, while managing profitability under competitive pressures [9] - The company anticipates leverage to remain within guidance levels despite recent acquisitions [9] PetroReconcavo - The company is maintaining flexibility in capital allocation, with expectations of double-digit production growth this year [12] - It recognizes the need for caution in the current oil price environment but does not plan significant CAPEX adjustments [12] Cosan - Committed to asset sales to improve its interest coverage ratio, with potential working capital pressures from recent IOF changes [13] - Raizen, one of Cosan's investees, is highlighted as being particularly exposed to these changes [13]

28 May 2025 | 6:02AM CEST Powering Up Europe Domestic, defensive and growing; a new era for Utilities Domestic, defensive and growing. Utilities operate predominantly domestic businesses with a large share of regulated or contracted profits (i.e., defensive). We expect the industry to positively surprise on organic growth, thanks to: (1) the inflection in power demand; (2) a pivot in capital allocation; and (3) the secular need to modernize the entire power system. In this context, we believe Utilities may ...